Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $21.3452W HIGH $58.40
Volume
15.31 M
Value Traded
836.06 M
Short % Float
6.27%
Days to Cover
4.0
+0.55%Week
+1.3%1 Month
+22.7%3 Month
-0.27%6 Month
+91.75%5 Year
+238.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.50 B
EPS (TTM)
-3.75
P/E Ratio
-
Ent. Value
3.76 B
Total Shares
79.99 M
Float Shares
67.03 M
Insiders
9.99%
Institutions
101.97%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
AKRO Catalyst Timeline
Dated clinical, regulatory and corporate events for Akero Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How AKRO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-10 | efruxifermin (EFX) | Phase 2b data presentation | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Efruxifermin Small moleculeNCT06161571 | NASH/MASH | Phase 3 | ACTIVE NOT_RECRUITING | 700 | Jun 19, 2026 | ||||||
| Efruxifermin Small moleculeNCT06215716 | NASH With Fibrosis | Phase 3 | RECRUITING | 1,650 | Feb 1, 2033 | ||||||
| Efruxifermin Small moleculeNCT04767529 | NASH - Nonalcoholic Steatohepatitis | Phase 3 | COMPLETED | 2,278 | May 2, 2024 | ||||||
| EFX Small moleculeCompletedNCT05039450 | NASH - Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 323 | Aug 28, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every AKRO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| efruxifermin | compensated cirrhosis due to MASH | Phase 2b | 2025-11-07 | antifibrotic effects of efruxifermin; 96-week Phase 2b SYMMETRY trial; potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH; fibrosis improvements observed through conventional pathology in the 96-week Phase 2b HARMONY trialRead More | Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rolph TimothyOfficer (Chief Scientific Officer) | Option | 3,527 132,998 held | $28.35 | 11/25/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in AKRO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 3.2 % (-23.8 %) | 260.07 M | 5.48 M |
Ownership Trends
AKRO Short Interest
Shares sold short, counted twice a month.
6.27%
Short % of Float
of tradable shares sold short
4.2M
Shares Sold Short
-2.8% vs prior count
4.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AKRO ranks across every disease it competes in
Competitive Position is a premium feature
See how AKRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAKRO News
About Akero Therapeutics, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next AKRO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime